Integra LifeSciences Revised FY23 Guidance For Revenue To $1.541B-$1.547B (From $1.548B- $1.560B) Vs. Consensus Of $1.55B; Adj. EPS To $3.10 to $3.14 (From $3.10 To $3.18) Vs. Consensus Of $3.14
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences has revised its FY23 guidance for revenue to $1.541B-$1.547B, down from the previous range of $1.548B-$1.560B. The consensus estimate was $1.55B. The company also adjusted its EPS forecast to $3.10-$3.14, from $3.10-$3.18, matching the consensus of $3.14.
October 25, 2023 | 10:09 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra LifeSciences has lowered its FY23 revenue and EPS guidance. This could potentially impact the company's stock price.
Integra LifeSciences has revised down its FY23 revenue and EPS guidance, which could lead to a negative sentiment among investors and potentially cause a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100